![Rita Balice-Gordon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rita Balice-Gordon
Direktor/Vorstandsmitglied bei COLLEGIUM PHARMACEUTICAL, INC.
Vermögen: 2 Mio $ am 31.05.2024
Profil
Rita Balice-Gordon is currently the Chief Executive Officer & Director at Muna Therapeutics ApS, an Independent Director at Collegium Pharmaceutical, Inc., and a Director at Capsida Biotherapeutics, Inc. She previously worked as the President-Neuroscience & Pain Research Unit at Pfizer Inc., the Global Head-Rare & Neurological Diseases at Sanofi, Inc., and as a Professor at Perelman School of Medicine.
Dr. Balice-Gordon completed her undergraduate degree at Northwestern University and her doctorate at The University of Texas at Austin.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
16.05.2024 | 46 488 ( 0,14% ) | 2 Mio $ | 31.05.2024 |
Aktive Positionen von Rita Balice-Gordon
Unternehmen | Position | Beginn |
---|---|---|
COLLEGIUM PHARMACEUTICAL, INC. | Direktor/Vorstandsmitglied | 24.09.2020 |
Muna Therapeutics ApS
![]() Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Vorstandsvorsitzender | - |
Capsida Biotherapeutics, Inc.
![]() Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Direktor/Vorstandsmitglied | 12.05.2021 |
Ehemalige bekannte Positionen von Rita Balice-Gordon
Unternehmen | Position | Ende |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Perelman School of Medicine | Corporate Officer/Principal | - |
Sanofi, Inc.
![]() Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Rita Balice-Gordon
Northwestern University | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
PFIZER, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Muna Therapeutics ApS
![]() Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Health Services |
Sanofi, Inc.
![]() Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a company based in New York, NY. | Retail Trade |
Capsida Biotherapeutics, Inc.
![]() Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Commercial Services |